作者
Jie Lian,Zhengxian Fan,Wei Fan,Shishir Rao,Qianqian Yang,Guyu Zeng,Ben Omega Petrazzini,Nouman Ahmed,Zeinab Bidel,Milad Nazarzadeh,Ron Do,Andrew Clegg,Małgorzata Wamil,Kazem Rahimi
摘要
BACKGROUND: Ageing is a key determinant of morbidity and mortality. In this study, we aimed to develop and assess a new ageing biomarker, ClinicalAge, derived from routinely collected longitudinal electronic health record (EHR) data. METHODS: In this model development and validation study, we used UK Biobank data for model development and UK Clinical Practice Research Datalink (CPRD) Aurum data for model validation. The UK Biobank is a longitudinal population-based cohort of approximately 500 000 individuals aged 40-69 years at recruitment (March 16, 2006, to Oct 1, 2010), with linked EHR from the November 2022 UK Biobank data release. CPRD Aurum is a primary care EHR database containing anonymised longitudinal data from over 30 million patients across the UK, including diagnoses, medication, procedures, and laboratory results. A transformer-based deep learning model was trained from longitudinal EHR data to generate ClinicalAge using the validated biomarker PhenoAge as reference. We used a UK Biobank cohort for model development and internal validation, and three CPRD Aurum cohorts for external validation, longitudinal trajectory analysis, and comparison with the electronic frailty index. ClinicalAge was evaluated for associations with 17 functional measures, ten biological ageing biomarkers, 31 ageing-related diseases (11 cancer diagnoses and 20 non-cancer diseases), and all-cause, cancer, and cardiovascular mortality. We further examined longitudinal ClinicalAge trajectories and investigated clinical and disease-specific factors associated with accelerated ageing. FINDINGS: score of 0·819 with PhenoAge and showed a significant association with the 17 functional measures and ten biological ageing biomarkers. It was also significantly associated with the incidence of all 20 non-cancer diseases in both datasets, as well as nine (82%) of 11 cancers in UK Biobank (seven positive associations and two negative) and ten (91%) of 11 cancers (eight positive associations and two negative) in CPRD. Moreover, ClinicalAge was significantly associated with all-cause mortality (UK Biobank adjusted hazard ratio [HR] 1·23 [95% CI 1·21-1·24]; CPRD adjusted HR 1·36 [1·36-1·36]), cancer mortality (UK Biobank adjusted HR 1·12 [1·10-1·14]; CPRD adjusted HR 1·17 [1·16-1·17]), and cardiovascular mortality (UK Biobank adjusted HR 1·33 [1·29-1·36]; CPRD adjusted HR 1·36 [1·35-1·36]), after adjustment for clinical covariates and lifestyle factors. Midlife was identified as a key window for divergence, with early acceleration in individuals developing diabetes, hypertension, depression, or lifestyle disorders. INTERPRETATION: ClinicalAge is a non-invasive biomarker that leverages routinely collected EHR data to quantify ageing across the life course. It shows strong associations with ageing-related biomarkers, functional decline, disease risk, and mortality. Its interpretability and anticipatory signal offer a practical tool for the early identification of individuals at risk of accelerated ageing, enabling targeted preventive strategies such as lifestyle modification, cardiometabolic control, and mental health support. FUNDING: None.